轻度阿尔茨海默病的衰老细胞清除治疗:一项1期可行性试验
这项开放标签、概念验证的1期临床试验在早期症状性阿尔茨海默病患者中评估口服达沙替尼联合槲皮素的中枢神经系统渗透性、安全性、可行性和疗效。5名参与者完成12周试点研究,达沙替尼在4名参与者脑脊液中可检测到,治疗耐受良好,无早期停药,认知和神经影像次要终点较基线无显著差异。
要点
- 达沙替尼在4名参与者脑脊液中检测到,槲皮素未检测到。
- 治疗耐受良好,无早期停药,认知和神经影像终点无显著差异。
- 脑脊液IL-6和GFAP升高,衰老相关细胞因子和趋化因子呈下降趋势。
核心结论
- 观察到达沙替尼的中枢神经系统渗透性,结果支持其在阿尔茨海默病患者中的安全性、耐受性和可行性。
- 生物标志物数据提供了衰老细胞清除效应的机制见解,需在充分把握度的安慰剂对照研究中确认。
研究设计与样本
- 开放标签、概念验证、1期临床试验,口服达沙替尼联合槲皮素。
- 5名早期症状性阿尔茨海默病患者完成12周试点研究,平均年龄76±5岁,女性占40%。
主要发现
- 所有参与者血中达沙替尼和槲皮素水平均升高(达沙替尼12.7-73.5 ng/ml,槲皮素3.29-26.3 ng/ml)。
- 4名参与者(80%)脑脊液中检测到达沙替尼,范围为0.281至0.536 ml-1,脑脊液与血浆比值为0.422-0.919%;槲皮素未检测到。
- 治疗耐受良好,无早期停药;认知和神经影像次要终点从基线至治疗后无显著差异。
- 脑脊液白细胞介素-6(IL-6)和胶质纤维酸性蛋白(GFAP)升高(t(4)=3.913,P=0.008和t(4)=3.354,P=0.028),衰老相关细胞因子和趋化因子呈下降趋势,Aβ42水平呈升高趋势(t(4)=-2.338,P=0.079)。
局限性
- 生物标志物数据提供的机制见解需在充分把握度的安慰剂对照研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cellular senescence contributes to Alzheimer's disease (AD) pathogenesis. An open-label, proof-of-concept, phase I clinical trial of orally delivered senolytic therapy, dasatinib (D) and quercetin (Q), was conducted in early-stage symptomatic patients with AD to assess central nervous system (CNS) penetrance, safety, feasibility and efficacy. Five participants (mean age = 76 + 5 years; 40% female) completed the 12-week pilot study. D and Q levels in blood increased in all participants (12.7-73.5 ng ml-1 for D and 3.29-26.3 ng ml-1 for Q). In cerebrospinal fluid (CSF), D levels were detected in four participants (80%) ranging from 0.281 to 0.536 ml-1 with a CSF to plasma ratio of 0.422-0.919%; Q was not detected. The treatment was well-tolerated, with no early discontinuation. Secondary cognitive and neuroimaging endpoints did not significantly differ from baseline to post-treatment further supporting a favorable safety profile. CSF levels of interleukin-6 (IL-6) and glial fibrillary acidic protein (GFAP) increased (t(4) = 3.913, P = 0.008 and t(4) = 3.354, P = 0.028, respectively) with trending decreases in senescence-related cytokines and chemokines, and a trend toward higher Aβ42 levels (t(4) = -2.338, P = 0.079). In summary, CNS penetrance of D was observed with outcomes supporting safety, tolerability and feasibility in patients with AD. Biomarker data provided mechanistic insights of senolytic effects that need to be confirmed in fully powered, placebo-controlled studies. ClinicalTrials.gov identifier: NCT04063124 .
引用
- Gonzales MM, Garbarino VR, Kautz TF, et al. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nat Med. 2023. PMID: 37679434. doi:10.1038/s41591-023-02543-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。